RecruitingPhase 3NCT06858319
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Studying Glomerular disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- zigakibart(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2025 – 2031
Study locations (6)
- Colorado Kidney Care Nephrology, Denver, Colorado, United States
- NY Nephrology, Clifton Park, New York, United States
- Knoxville Kidney Center Pllc, Brentwood, Tennessee, United States
- Novartis Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina
- Novartis Investigative Site, Santa Fe, Argentina
- Novartis Investigative Site, Seoul, Korea, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06858319 on ClinicalTrials.govOther trials for Glomerular disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05839314Effect of Huaier Granule on the Treatment of Idiopathic Membranous NephropathyChinese PLA General Hospital
- RECRUITINGNCT05505500Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.University of Michigan
- RECRUITINGNCT04528446The Impact of Glomerular Disorders on Bone Quality and StrengthColumbia University
- RECRUITINGNCT03929887KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisSeoul National University Hospital
- RECRUITINGNCT02954419IgA Nephropathy Biomarkers Evaluation Study (INTEREST)Sun Yat-sen University
- RECRUITINGPHASE2NCT00977977Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)